Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tianjin Tianyao Pharmaceutical (officially renamed Jinyao Pharmaceutical Co., Ltd. in 2022) is a leading China-based pharmaceutical company specializing in the research, development, production, and sale of corticosteroid and amino acid active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1939 and listed on the Shanghai Stock Exchange in 2001, the company is one of the world's largest manufacturers of steroid hormones, offering a portfolio of over 40 corticosteroid varieties (such as dexamethasone, prednisone, and methylprednisolone) and 23 amino acid APIs. Its finished preparations span multiple dosage forms, including injections, ointments, creams, tablets, and inhalation preparations. With GMP certifications from the US FDA, European EDQM, and other global regulatory bodies, the company exports its products to over 70 countries and regions while also operating as a domestic CDMO base.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tianjin Tianyao Pharmaceutical.